8 brokers have issued 12 month price objectives for Novo Nordisk A/S's shares. Their NVO share price targets range from $110.00 to $163.00. On average, they expect the company's share price to reach $133.60 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
Should you buy NVO (NVO) stock?
There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVO shares. View NVO analyst ratings or view top-rated stocks.
Does Novo Nordisk A/S (NVO) have a biopharmaceutical segment?
Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. Find the latest Novo Nordisk A/S (NVO) stock quote, history, news and other vital information to help you with your stock trading and investing.
